logo
I Went to War With Fungus Gnats. This Is the Secret Weapon That Helped Me Win.

I Went to War With Fungus Gnats. This Is the Secret Weapon That Helped Me Win.

New York Times22-05-2025

When a flying bug comes my way, rational thought goes out the window. With high-pitched squeals and eyes shut, I'll bat the air, hoping to hit a line drive with the helpless creature. But more often than not, it's a swing and a miss.
So you can imagine my horror when my indoor plants became infested with hundreds, if not thousands, of fungus gnats in the summer of 2020. My batting average was as low as my mental state as I unsuccessfully feuded against a swarm of tiny flies for weeks. When I thought I had finally gotten rid of them, a new platoon would emerge, ready to pick a fight.
Desperation kicked in when every method I tried failed, from insecticides to homemade traps. Until, at last, I hit a walk-off grand slam by staking Garsum Fruit Fly Sticky Traps at the base of each plant. Once they were installed, it took only a few days to strike out the entire army of gnats without breaking a sweat.
Since then, these sticky traps have been permanently nestled in the soil of my houseplants and clipped onto the fruit bowls in my kitchen as a frontline defense for keeping unwelcome bugs from invading my home.
These sticky fly traps are designed to attract and capture insects that land or crawl onto the surface. Within a week of installing the sticky traps, my coworker Megan Beauchamp managed to capture several gnats hanging around her African violet. Megan Beauchamp/NYT Wirecutter
Though fungus gnats are harmless to humans, they can wreak havoc on plants. The larvae live in soil and feed on fungi, organic matter, and occasionally a plant's roots, which can cause a once-thriving anthurium to go dry, lose its vigor, and even decay.
It doesn't help that fungus gnats can reproduce surprisingly quickly. Mated females lay 100 to 200 microscopic eggs at a time, and they hatch a mere four to six days later, according to information published by Utah State University Extension and Utah Plant Pest Diagnostic Laboratory. Once the larvae are born, they'll feed (on soil and plant roots) for about 15 days before spinning into a cocoon to transition into adulthood — a speedy five-to-six-day turnaround.
In a fit of desperation, I used the adhesive side of a sticky note as my weapon of choice against these gnats, which worked on a small scale, but it led me to believe something better might already be on the market. I was right, and a quick TikTok search pointed me toward my beloved sticky traps — hundreds of videos confirmed their lethal capabilities.
The fungus gnats were finally outmatched. A week after I put in the Garsum sticky traps, the flies were completely eradicated — aside from the proof of their lifeless corpses stuck onto the traps. The paper lining keeps the adhesive material from sticking until you're ready to use them. Maki Yazawa/NYT Wirecutter
The yellow traps are designed to attract (due to the bright color) and capture (thanks to the super-sticky adhesive) any insect that lands or crawls onto them. They're long-lasting, durable, UV-resistant, and waterproof, so they're ideal for indoor or outdoor use (although I've only used them inside).
They come in various designs with simple cutout silhouettes of butterflies, birds, and succulents and, on average, are about the size of an index card. The bottom portion of the trap has a pointed triangular shape, which makes it easier to stake it into the ground or a potted plant. But if you're having trouble inserting one, I've found that piercing the soil first with a butter knife or the plastic mini shovel tool that comes with the traps works well.
To install, simply peel off the paper lining on both sides of the trap to reveal the adhesive material. Then, position it upright in the soil so that it's not too close to the plant's stems and leaves but close enough to get in the way of an insect's flight path.
These highly effective sticky traps caught dozens of pesky bugs at a time. Even though I don't consider myself the murderous type, I marveled at the sight of the lifeless gnats pinned to the sticky surface. It was as oddly satisfying as taking in the infamous Gum Wall at Pike Place Market in Seattle — equally gross and gratifying. Left: The plants that were affected by the 2020 gnat infestation, after the sticky traps successfully eradicated the bugs. Right: The sticky traps protecting plants in our Long Island City, New York, office. Maki Yazawa/NYT Wirecutter
The manufacturer says these sticky traps are also effective against other small airborne insects, like whiteflies, aphids, thrips, midges, leaf miners, mosquitoes, and fruit flies.
In the five years that I've used the traps, I've also successfully taken on fruit flies, and I've made a habit of clipping a trap onto the side of my fruit bowl to prevent infestations from occurring. You can also prop them up near a trash can for similar results. I clip a sticky trap on my fruit bowl to trap fruit flies. Maki Yazawa/NYT Wirecutter
When I'm not dealing with a full-blown infestation, the traps last several months, and I only toss and replace them once they're too polka-dotted with bugs to work effectively.
My only qualm with this product is that the sticky material can get on your fingers, but an alcohol-based hand sanitizer or a few drops of vegetable oil can help soften it enough to rinse away. The manufacturer also notes that the glue can melt when exposed to heat, but I've found that briefly refrigerating the traps can help reconstitute the material.
Fortunately, the adhesive doesn't inflict damage on a plant's leaves even if you accidentally touch one with a trap. In my experience, I've been able to carefully peel away any stuck-on leaves with minimal damage.
Still, the pros far outweigh the cons, and I appreciate how hands-off this extermination method is. Long gone are the days of risking injury while batting flying insects away.
If only solving all my critter concerns could be this easy. But a win's a win, and in my book, these sticky traps are a home run.
This article was edited by Megan Beauchamp and Maxine Builder. Here's the best gear for killing flies and other common household pests.
Our repellent recommendations are EPA approved, backed by experts, and tested by us.
Create a bug-free bubble outdoors with these spatial insect repellents.
Bug zappers kill the wrong bugs—to control bugs without a spray repellent, use a spatial repellent or a fan instead.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Which Class of ER Degrader Is Better?
Which Class of ER Degrader Is Better?

Medscape

time16 minutes ago

  • Medscape

Which Class of ER Degrader Is Better?

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), outshone the commonly used selective estrogen receptor degrader (SERD) fulvestrant in a phase 3 trial of second-line treatment for a subset of patients with breast cancer. The VERITAC-2 trial included patients with ER-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-), locally advanced or metastatic disease who had failed prior treatment with cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and endocrine therapy, and no exposure to chemotherapy in the advanced setting. Only a subset of the study cohort, those with estrogen receptor 1-mutant disease, experienced a statistically significant and clinically meaningful improvement in progression-free survival (PFS) when treated with vepdegestrant compared with patients treated with fulvestrant. 'These results support vepdegestrant as a potential monotherapy treatment option for patients with previously treated ESR1 -mutant ER+/HER2- advanced breast cancer,' said lead author Erika P. Hamilton, MD, a medical oncologist and director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, Nashville, Tennessee, during a press conference for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings were simultaneously published in the New England Journal of Medicine . Vepdegestrant is not approved by the US Food and Drug Administration, but received fast-track status in February 2024 as monotherapy for this patient population. It is the first and only PROTAC ER degrader to be evaluated in a phase 3 clinical trial in breast cancer. PROTACs represent a novel class of therapeutic agents that harness the proteasome to selectively degrade target proteins. 'There's no established consensus for patients getting treatment in the second-line setting after progression on endocrine therapy and a CDK 4/6 inhibitor,' explained Hamilton. 'One of the mainstays of our treatment really has been fulvestrant, which clearly has some challenges. First, it's administered intramuscularly, and second, in a post-CDK 4/6 landscape, we know that progression-free survival is very short — on the order of less than 2 months.' Besides fulvestrant, the oral SERD elacestrant was FDA-approved in January 2023, and other oral SERDs are in development, she noted. Trial Design The new trial included 624 patients with advanced ER+/HER2- disease that had progressed following one or two lines of endocrine therapy and a CDK 4/6 inhibitor. 'They could not have received fulvestrant already or chemotherapy, and patients had to have benefited from their previous line of endocrine therapy for at least 6 months to enter the study,' Hamilton noted. Study participants were also stratified by the presence or absence of visceral disease, as well as the presence of an ESR1 mutation (n = 270). Such mutations are a common cause of acquired resistance found in approximately 40% of patients in the second-line setting, according to a press release from the drug developer. Patients were randomly assigned 1:1 to 28-day treatment cycles of either 200 mg oral vepdegestrant once daily, or 500 mg intramuscular fulvestrant on day 1 and day 15 of the first cycle, and then on day 1 of each subsequent cycle. The primary endpoint was PFS by blinded, independent central review, first in patients with ESR1 mutations and then in the entire cohort. Key secondary endpoints were overall survival, objective response rate, and clinical benefit rate, which was defined as the rate of confirmed clinical or partial response at any time, or stable disease, nonclinical response, or nonprogressive disease for at least 24 weeks. Vepdegestrant vs Fulvestrant The study met its key primary endpoint, showing a median PFS of 5.0 months with vepdegestrant compared with 2.1 months with fulvestrant (hazard ratio [HR] 0.57; P < .001) in the 270 patients with ESR1 mutations. At 6 months, twice as many patients in the vepdegestrant arm remained progression-free compared with those in the fulvestrant arm (45.2% vs 22.7%). However, this primary endpoint was not significantly different between groups when calculated for the entire patient population (HR, 0.83; P = .07). For the key secondary endpoints, among patients with ESR1 mutations, the clinical benefit rate was more than double in patients receiving vepdegestrant (42.1% vs 20.2%). Similarly, the objective response rate was more than four times higher (18.6% vs 4%) Commenting in a press release, ASCO breast cancer expert Jane Lowe Meisel, MD, said that although the trial found that vepdegestrant worked better than fulvestrant in patients with ESR1 mutations, 'on average, patients did not have prolonged responses on either agent, highlighting the need for combination therapies and continued development in this space.' Meisel is co-director of Breast Medical Oncology at the Winship Cancer Institute of Emory University School of Medicine in Atlanta, Georgia. 'Overall survival was very immature at the time of this analysis, with only 20% of the anticipated events occurring,' added lead investigator Hamilton. Treatment-emergent adverse events (TEAEs) led to discontinuation in 3% of patients taking vepdegestrant and 1% of patients taking fulvestrant. TEAEs leading to dose reductions occurred in 2% of the vepdegestrant group and none in the fulvestrant group. The three most common AEs of any grade were fatigue (27% in vepdegestrant group, 16% fulvestrant group) and increased aspartate aminotransferase and alanine aminotransferase levels of any grade (14% vepdegestrant group, 10% fulvestrant group). Oral SERDS vs Vepdegestrant Side Effects Compared to oral SERDs, vepdegestrant has a favorable side effect profile, Hamilton said. 'Oral SERDs have prominent GI side effects as their most frequent side effect.' But, across all grades, rates of both vomiting and diarrhea were only 6% with vepdegestrant. GI side effects tend to be more common, 'in the 30% or 40% range with oral SERDs,' she told Medscape Medical News . Study discussant William John Gradishar, MD, emphasized the importance of reducing side effects. ' Vepdegestrant now joins a growing list of drugs that perform better than current standard of care monotherapy' in the ESR1 -mutant population, he noted in the session. But the reality is that most of these drugs are being developed to be used in combination with targeted therapies, 'and increased toxicity can be expected with doublet therapy…Quality of life measures as experienced and reported by patients are critical, and even modest changes in symptom and functional domains should not be minimized,' said Gradishar, professor of breast oncology at Northwestern University Feinberg School of Medicine, Chicago, Illinois. 'Vepdegestrant has demonstrated compelling preclinical activity and encouraging early clinical data supporting its efficacy in degrading ER,' said Albert Grinshpun, MD, in an interview with Medscape Medical News . Grinshpun, head of the Breast Cancer Service at Shaare Zedek Medical Center and The Hebrew University, Jerusalem, Israel, said his initial takeaway from the study is that 'vepdegestrant now stands alongside other oral SERDs, such as elacestrant and imlunestrant, in demonstrating superiority over fulvestrant, specifically in the context of ESR1­ -mutant [disease].' 'Importantly, the treatment landscape for patients progressing on CDK 4/6 inhibitors is rapidly evolving, with a growing shift toward combination therapies rather than fulvestrant monotherapy,' he said. 'In my view, vepdegestrant has established itself as a promising endocrine backbone for future combination strategies. Its favorable toxicity profile makes it particularly well-suited for pairing with a range of targeted agents or even antibody-drug conjugates, including inhibitors of PIK3CA and KAT6 , in the pursuit of more effective therapeutic regimens.' The study was jointly funded by Arvinas Estrogen Receptor, Inc. and Pfizer. Hamilton disclosed consulting or advisory roles with Accutar Biotechnology (Inst), Arvinas (Inst), AstraZeneca (Inst), Circle Pharma (Inst), Daiichi Sankyo (Inst), Ellipses Pharma (Inst), Entos (Inst), Fosun Pharma (Inst), Genentech/Roche (Inst), Gilead Sciences (Inst), Janssen (Inst), Jazz Pharmaceuticals (Inst), Jefferies (Inst), Johnson & Johnson (Inst), Lilly (Inst), Medical Pharma Services (Inst), Mersana (Inst), Novartis (Inst), Olema Pharmaceuticals (Inst), Pfizer (Inst), Stemline Therapeutics (Inst), Tempus (Inst), Theratechnologies (Inst), Tubulis GmbH (Inst), Verascity Science (Inst), and Zentalis (Inst). Hamilton has also received research funding from AbbVie (Inst), Accutar Biotech (Inst), Acerta Pharma (Inst), ADC Therapeutics (Inst), Akeso Biopharma (Inst), Amgen (Inst), Aravive (Inst), ArQule (Inst), Artios (Inst), Arvinas (Inst), AstraZeneca (Inst), AtlasMedx (Inst), BeiGene (Inst), Black Diamond Therapeutics (Inst), Bliss Biopharmaceutical (Inst), Boehringer Ingelheim (Inst), Bristol-Myers Squibb (Inst), Cascadian Therapeutics (Inst), Clovis Oncology (Inst), Compugen (Inst), Context Therapeutics (Inst), Cullinan Oncology (Inst), Curis (Inst), CytomX Therapeutics (Inst), Daiichi Sankyo (Inst), Dana-Farber Cancer Institute (Inst), Dantari (Inst), Deciphera (Inst), Duality Biologics (Inst), eFFECTOR Therapeutics (Inst), Eisai (Inst), Ellipses Pharma (Inst), Elucida Oncology (Inst), EMD Serono (Inst), Fochon Pharmaceuticals (Inst), Fujifilm (Inst), G1 Therapeutics (Inst), Genentech/Roche (Inst), Gilead Sciences (Inst), H3 Biomedicine (Inst), Harpoon (Inst), Hutchison MediPharma (Inst), Immunogen (Inst), Immunomedics (Inst), Incyte (Inst), Infinity Pharmaceuticals (Inst), Inspirna (Inst), InventisBio (Inst), Jacobio (Inst), K-Group Beta (Inst), Karyopharm Therapeutics (Inst), Kind Pharmaceuticals (Inst), Leap Therapeutics (Inst), Lilly (Inst), Loxo (Inst), Lycera (Inst), MabSpace Biosciences (Inst), Macrogenics (Inst), MedImmune (Inst), Mersana (Inst), Merus (Inst), Millennium (Inst), Molecular Templates (Inst), Myriad Genetics (Inst), Novartis (Inst), Nucana (Inst), Olema Pharmaceuticals (Inst), OncoMed (Inst), Oncothyreon (Inst), ORIC Pharmaceuticals (Inst), Orinove (Inst), Orum Therapeutics (Inst), Pfizer (Inst), PharmaMar (Inst), Pieris Pharmaceuticals (Inst), Pionyr (Inst), Plexxikon (Inst), Prelude Therapeutics (Inst), ProfoundBio (Inst), Radius Health (Inst), Regeneron (Inst), Relay Therapeutics (Inst), Repertoire Immune Medicines (Inst), Rgenix (Inst), Seagen (Inst), Sermonix Pharmaceuticals (Inst), Shattuck Labs (Inst), Silverback Therapeutics (Inst), Stem CentRx (Inst), Stemline Therapeutics (Inst), Sutro Biopharma (Inst), Syndax (Inst), Syros Pharmaceuticals (Inst), Taiho Pharmaceutical (Inst), TapImmune Inc. (Inst), Tesaro (Inst), Tolmar (Inst), Torque (Inst), Treadwell Therapeutics (Inst), Verastem (Inst), Zenith Epigenetics (Inst), and Zymeworks (Inst). Meisel disclosed consulting or advisory roles with AstraZeneca, GE Healthcare, Genentech, Novartis, Olema Oncology, Pfizer, SeaGen, Sermonix Pharmaceuticals, and Stemline, and research funding from AstraZeneca (Inst), Olema Oncology (Inst), Pfizer (Inst), Seagen (Inst), and Sermonix Pharmaceuticals (Inst). Grinshpun disclosed honoraria from GSK, Lilly, Novartis, and AstraZeneca, and travel from Roche, Pfizer, and AstraZeneca. Gradishar disclosed consulting or advisory roles with AstraZeneca , Genentech/Roche, Gilead Sciences, Merck, Novartis, Pfizer.

Transcript: Rep. Raja Krishnamoorthi on "Face the Nation with Margaret Brennan," June 1, 2025
Transcript: Rep. Raja Krishnamoorthi on "Face the Nation with Margaret Brennan," June 1, 2025

CBS News

time21 minutes ago

  • CBS News

Transcript: Rep. Raja Krishnamoorthi on "Face the Nation with Margaret Brennan," June 1, 2025

The following is the transcript of an interview with Rep. Raja Krishnamoorthi, Democrat of Illinois, that aired on "Face the Nation with Margaret Brennan" on June 1, 2025. MARGARET BRENNAN: We turn now to the top Democrat on the House Select Committee on the Chinese Communist Party, that's Congressman Raja Krishnamoorthi. He's in Illinois. Good morning to you. I want to get-- REP. KRISHNAMOORTHI: --Good morning. MARGARET BRENNAN: I want to get straight to it. You heard from the Secretary of State this week that the State Department is going to work with Homeland Security to aggressively revoke visas for Chinese students, including those with connections to the Chinese Communist Party or studying in critical fields. There are like 300,000 Chinese students with visas in this country. The U.S. government already has a heightened level of vetting. What's going to change? REP. KRISHNAMOORTHI: I don't know. There's not enough details, but what it looks like if they're targeting all people of Chinese origin who are on international student visas because he's not limiting it to just people who might have ties to the Chinese Communist Party, and if they do have those ties, they don't belong here, especially if they're committing nefarious acts. However, this appears to be much broader and it's terribly misguided and it appears prejudicial and discriminatory. My own father was, came here on an international student visa. And I believe that these people are vital for our economy and for entrepreneurship in this country. And I think this is going to harm America more than help. MARGARET BRENNAN: You said if someone has ties to the Chinese Communist Party they shouldn't be here. Does that mean all the, the students who are children of leaders, for example Xi Jinping's own daughter, shouldn't have been allowed here? REP. KRISHNAMOORTHI: Well, if they were engaged in nefarious activities and if they are somehow deeply connected to the CCP, I think that we should be very careful. But in this particular case, they're not only going after people who might fall in that category, but it's anybody who is from China, including Hong Kong by the way, where people are actually persecuted for various freedoms they're trying to exercise, and who come here seeking to exercise those freedoms. So this is a terrible, terribly misguided policy. MARGARET BRENNAN: The Biden administration did conduct heightened vetting, as you know, of Chinese students. Do you think that there is a legitimate argument for expanding this, that certain areas should just be off limits? REP. KRISHNAMOORTHI: I think that you should definitely have heightened vetting, especially in certain critical areas because we know that the CCP tries to steal, for instance, intellectual property or worse. But the way that this is currently structured looks very, very suspicious and you have to remember that the people that are cheering for this policy, what Marco Rubio had called for, is the Chinese Communist Party. Why? Because they want these people back. They want the scientists and the entrepreneurs and the engineers who can come and help their economy. And so we are probably helping them, as well as other countries, more than helping ourselves with this policy. MARGARET BRENNAN: The Defense Secretary is traveling in Asia right now and he said in a defense forum speech that Beijing is quote "concretely and credibly preparing to use military force." He said their military is rehearsing. Take a listen. PETE HEGSETH: Any attempt by Communist China to conquer Taiwan by force would result in devastating consequences for the Indo-Pacific and the world. There's no reason to sugar coat it. The threat China poses is real and it could be imminent. MARGARET BRENNAN: He did not say what the consequences would be. Are you encouraged by what appears to be a statement of support for allies? REP. KRISHNAMOORTHI: I am. I think what he's saying is largely correct, but I think the problem is at the same time he says that, either Donald Trump or even him or others say other things that push away our friends, partners and allies in the region and cause confusion. And so we need to be consistent and thoughtful with regard to our statements, and we need to be also very methodical about our actions in trying to curb military aggression by the Chinese Communist Party in the South China Sea and with regard to Taiwan. MARGARET BRENNAN: Since you track U.S. intelligence, I wanted to ask you if you have any insight into what appears to be the swarm of Ukrainian drones that has destroyed 40 Russian military aircraft deep inside Russian territory overnight. Sources are telling our Jennifer Jacobs that the White House wasn't aware that this attack was planned. What can you tell us about the level of US intelligence sharing with Ukraine right now and helping them with their targets? REP. KRISHNAMOORTHI: I don't want to get into classified information, but what I can say is that it's a little bit more strained in light of what Donald Trump has said recently. The one thing that I can also say is that Trump was right the other day to say that Putin is crazy in the way that he's going after civilian areas in Ukraine repeatedly, and so the Ukrainians are striking back. At the end of the day, the only way that we can bring these hostilities to an end is by strengthening the hand of the Ukrainians. Trump should, at this point, realize that Putin is playing him and aid the Ukrainians in their battlefield efforts. That's the best way to get to some type of armistice or truce at the negotiating table sooner rather than later. MARGARET BRENNAN: All right, Congressman Krishnamoorthi thank you for your insights today.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store